The following discussion and analysis of financial condition and results of
operations should be read in conjunction with our financial statements and
related notes included elsewhere in this report. This discussion contains
forward-looking statements that involve risks, uncertainties and assumptions.
See "Forward-Looking Statements."
Overview
Since January 30, 2017, following a change of control, we have been engaged in
the business of developing and marketing nutritional products that promote
wellness and a healthy lifestyle. Our business to date has involved the purchase
of products from three suppliers in the Republic of China and the sale of these
products to three unrelated customers, one of which accounted for all of our
sales in the quarters ended March 31, 2020 and December 31, 2019, which were our
only sales in the nine months ended September 30, 2020 and year ended December
31, 2019. We did not have any sales during the three months ended September 30,
2020, the three months ended June 30, 2020 or first three quarters of the year
ended December 31, 2019. We sell product in bulk to companies who may use our
products as ingredients in their products or sell the products they purchase
from us to their own customers.
All of our sales to date have been sales of cordyceps related products and, in
the quarter ended March 31, 2018, metallothionein MT-3 elizer. Cordyceps is a
fungus that is used in traditional Chinese medicine. Cordyceps sinensis has been
described as a medicine in old Chinese medical books and Tibetan medicine. It is
a rare combination of a caterpillar and a fungus and found at altitudes above
4500m in Sikkim. Our present inventory and inventory deposit are for cordyseps
products. The encoded protein in metallothionein MT-3 is a growth inhibitory
factor, and reduced levels of the protein are observed in the brains of
individuals with some metal-linked neurodegenerative disorders such as
Alzheimer's disease. We have not sold metallothionein MT-3 elizer since the
quarter ended March 31, 2018, and we do not have any orders for metallothionein
MT-3 elizer. We cannot assure you that we will be able to sell metallothionein
MT-3 elizer in the future. We may also seek to market other products which we
see as complimentary to our present products; however, we have not entered into
negotiations with respect to the distribution of other products and we cannot
assure you that we will be able to market any other products.
All of our revenue for the nine months ended September 30, 2020 represents sales
to one customer, all of which were made during the three months ended March 31,
2020. There were no sales during the three months ended June 30, 2020 or the
three months ended September 30, 2020. We believe that our failure to sell
products in the six months ended September 30, 2020 resulted substantially from
the COVID - 19 pandemic and actions taken by governments to address the
pandemic. We believe our failure to generate sales reflects a downturn in the
market in the PRC for cordyseps products as well as the political conditions in
Hong Kong, and we cannot assure you that the market will improve. We also cannot
assure you the political instability in Hong Kong will not affect our sales,
since our customers in 2017 and 2018 were Hong Kong based customers who sold
their products in the People's Republic of China (the "PRC") and none of these
customers has made purchases from us since the quarter ended December 31, 2018.
We cannot assure you that these factors will not affect our ability to generate
revenues in the future and, to the extent that any of these factors affects our
ability to generate revenue, we may not be able to continue in business.
At present, we have no full-time employees. Our only employee is our chief
executive officer who works for us on a part-time basis, and all of our sales to
date have been made by our chief executive officer. We plan to develop a
marketing program pursuant to which we will seek to:
• market raw materials to customers, primarily in Hong Kong, who would use
our products as an ingredient on their products;
• enter into agreements with customers pursuant to which we would develop
and supply products which include our ingredients and which meet the
specifications of the customer;
• develop one or more products which we would sell to retail outlets which
would sell our products to their customers or sell the products directly
to retail customers as on-line sales.
We do not presently have either a marketing staff or any manufacturing
facilities. We intend to develop a marketing staff by hiring a marketing manager
and engaging independent sales representatives or hiring sales and marketing and
sales personnel or a combination of independent representatives and sales staff.
We cannot assure you that we will be able to engage the necessary qualified
personnel or to implement an effective marketing program.
12
Table of Contents
We face significant risks in implementing our business plan including, but not
limited to, our ability to raise the necessary financing either through the sale
of debt or equity securities or through a loan facility, our ability to increase
our customer base and supply chain, our ability to increase our gross margins,
our ability to hire and retain qualified research and development, marketing and
administrative personnel, our ability to develop products and to market in the
United States and other western markets any products we may develop, our ability
to comply with any government regulations relating to the manufacture,
distribution and marketing any products we develop. We cannot assure you that we
can or will develop any products or generate revenue or profits in the future.
Although our business plan initially contemplated that we would conduct research
and development on our own proprietary products based on cordyceps sinensis, to
date we have neither commenced such activities nor take any preliminary steps
with respect to such activities. We do not presently have the funds necessary
for us to engage in such activities, and we cannot assure you that we will be
able to commence any research and development activities or that any such
activities that we may undertake will be successful.
We require funds for our operations. At September 30, 2020, we had $156 cash and
cash equivalents, $938,000 of inventory of cordyceps products and a $12,000
purchase deposit for cordyceps products inventory. Although we may seek to raise
funds in the equity market, we have no agreements or understandings with respect
to any funding and we can give no assurance as to the availability or terms of
any such financing. Because of our financial condition, the lack of sales in the
six months ended September 30, 2020 or first nine months of 2019 and only modest
sales in the fourth quarter of 2019 and the first quarter of 2020, our reliance
of sales primarily of one product, along with the absence of an active market
for our stock and our market capitalization in relation to our financial
performance, together with risks related to the COVID-19 pandemic and the
political and legal situation in Hong Kong, it may be difficult for us to raise
funds in the equity market, and, if we are able to raise funds our stockholders
may suffer significant dilution.If we cannot raise necessary funds, we may be
unable to implement our business plan.
To the extent that we implement our business plan, we anticipate that we will
incur marketing and other expenses without any assurance that such expenses will
generate any significant revenue or net income. Because of our cash position, we
may use equity-based compensation for our employees and independent contractors.
In August 2020, we adopted our 2020 long-term incentive plan, pursuant to which
up to 12,000,000 shares can be issued. In order to pay cash expenses, we may
have to rely on loans from stockholders or related parties, although we do not
have any agreements or understandings at this time.
Effects of COVID-19
Since our products are purchased by customers in Hong Kong either as one
ingredient of a product to be sold to their customers or to be resold to their
customers, our business has been and may continue to be impacted by the effects
of the COVID-19 pandemic and the actions taken by the governments of the PRC,
Hong Kong and the Republic of China ("Taiwan") as they effect manufacturers and
their customers. Since we had modest sales in the three months ended March 31,
2020 as well as the year ended December 31, 2019, with sales in only the last
quarter of 2019, we cannot predict the effect of COVID-19 on our business. A
prolonged outbreak could have a material adverse impact on our financial results
and business operations. Factors relating to COVID-19 which significantly
contributed to our lack of revenue in the three months ended September 30, 2020,
may affect us and the market for our products include, but are not limited to,
the following.
• The effect of COVID-19 on the ability of our customers and potential
customers to manufacture products.
• The financial health of our potential customers.
• Since our customers may use our products as an ingredient in their
products, the inability of the customer to obtain other ingredients may
affect their willingness or ability to purchase our product.
• The ability of our customers to ship their products to China and the
ability of their customers to distribute product to retail markets.
• The willingness or ability of the ultimate purchasers in the PRC and any
other countries to which our customers sell products to purchase products
with our ingredients and their perception as to whether the products may
have beneficial effects to them.
• The extent to which any quarantine which may be imposed affects the
willingness or ability of consumers to purchase products with our
ingredients.
• The perceived benefit, if any, to consumers of products with our
ingredients.
• The extent to which the purchase of products with our ingredients is a low
priority item for a population whose disposable income may have decreased
as a result of COVID-19 and the steps taken by governments to curb the
spread of infection.
13
Table of Contents
Results of Operations
Three and Nine Months Ended September 30, 2020 and 2019.
For the three months ended September 30, 2020, we had no revenue, operating
expenses of $71,541, primarily professional fees relating to our status as a
public company, interest expense to a related party of $1,558 and a net loss of
$73,099, or $(0.00) per share (basic and diluted).
For the three months-ended September 30, 2019, we had no revenues, operating
expenses of $64,460, primarily professional fees related to our status as a
public company, interest expense to a related party of $826, a loss before
income taxes of $65,286, an income tax provision of $9,871, and a net loss of
$75,157 or $(0.00) per share (basic and diluted).
For the nine months ended September 30, 2020, we had revenue of $687,964,
representing sales of cordyceps products from one customer during the first
quarter of the year. Our cost of revenue was $528,560, our gross profit was
$159,404, and our gross margin was 23.17%. Our operating expenses were $212,159,
primarily professional fees relating to our status as a public company, our
interest expense to a related party was $2,927 and we had a net loss of $55,682,
or $(0.00) per share (basic and diluted).
For the nine months ended September 30, 2019 we had no revenue, operating
expenses of $347,318, consisting of stock-based compensation to consultants of
$148,395, and other general and administrative expenses of $198,923, primarily
professional fees relating to our status as a public company, interest expense
to a related party of $1,543, a loss before income tax credit of $348,861, an
income tax credit of $53,130, and a net loss of $295,731, or $(0.01) per share
(basic and diluted).
Because of our dependence on a few customers, one of which accounted for all of
our sales since January 1, 2019, our revenue in any quarter is dependent upon
both the timing of orders from customers and the delivery of products from our
suppliers.
Liquidity and Capital Resources
The following table summarizes our changes in working capital from December 31,
2019 to September 30, 2020:
September 30, December 31,
2020 2019 Change % Change
Current assets $ 954,156 $ 879,471 $ 74,685 8.5 %
Current liabilities $ 239,889 $ 111,541 $ 128,348 115.1 %
Working capital $ 714,267 $ 767,930 $ (53,663 ) (7.0 )%
Our principal current asset is inventory, which was $938,000 at September 30,
2020 and $878,560 at December 31, 2019. To the extent that we are not able to
sell our inventory, our working capital will be materially impaired.
The following table summarizes our cash flows for the nine months ended
September 30, 2020 and 2019:
Nine months Ended
September 30,
2020 2019
Cash (used in) operating activities $ (162,446 ) $ (94,637 )
Cash provided by financing activities 161,691 58,502
Cash and cash equivalents end of period 156 1,472
14
Table of Contents
Cash used in operating activities of $162,446 for the nine months ended
September 30, 2020 reflected primarily our net loss of $55,682 decreased
primarily by an increase in inventory of $59,440 and a purchase deposit for
inventory of $12,000, a decrease in accounts payable and accrued expenses of
$18,762, and a decrease of deferred revenue of $17,464.
Cash used in operating activities of $94,637 for the nine months ended September
30, 2019 reflected primarily our net loss of $295,731, decreased primarily by
stock-based compensation of $148,395, and a deferred tax asset of $19,941, and
increased by an increase in deferred revenue of $116,000, adjustment in income
tax payable $73,071 and income tax payable of $19,156.
Cash used in financing activities of $161,691 for the nine months ended
September 30, 2020 represented advances from related parties. Cash used in
financing activities of $58,502 for the nine months ended September 30, 2019
represented advances from related parties of $103,502 less repayment to related
parties of $45,000.
Going Concern
The accompanying unaudited financial statements have been prepared assuming that
we will continue as a going concern, which contemplates the realization of
assets and the liquidation of liabilities in the normal course of business. We
had minimal cash as of September 30, 2020 and did not generate cash from its
operation for the nine months ended September 30, 2020 and we had no sales in
the six months ended September 30, 2020 and minimal sales in the three months
ended March 31, 2020 and, during the year ended December 31, 2019, we only had
sales in the fourth quarter. These factors, among others, raise substantial
doubt about our ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of this
uncertainty.
We propose to fund operations through sales of its products and equity financing
arrangements. We plan to introduce a marketing effort to market our products,
however, we cannot give any assurance as to our ability to implement a marketing
program or to generate revenue or net income from these efforts. Further, we did
not have any sales during the six months ended September 30, 2020, do not have
any agreements or understanding with respect to any financing and, because of
the lack of sales and the absence of any active trading market for our common
stock, our financial condition and our lack of an operating history, we may not
be able to raise funds for capital expenditures, working capital and other cash
requirements. Our ability to implement our proposed marketing plan may also be
affected by the COVID-19 pandemic and actions taken by governments to address
the pandemic as well as political events and legislation in Hong Kong. If we
cannot generate revenue from our products, we may not be able to continue in its
business.
Critical Accounting Policy and Estimates
Our critical accounting policies are disclosed in Note 2 or Notes to Financial
Statements.
Recent Accounting Pronouncements
Management has considered all recent accounting pronouncements. Our management
believes that these recent pronouncements will not have a material effect on our
financial statements.
15
Table of Contents
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably
likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that is material to investors.
© Edgar Online, source Glimpses